REDMOND,
Wash., May 23, 2024 /PRNewswire/ -- SystImmune,
Inc., a pioneering clinical-stage biopharmaceutical company focused
on developing novel therapeutic bi-specific, multi-specific
antibodies, and antibody-drug conjugates (ADCs) for the treatment
of cancer, today announced the appointment of Dr. Jonathan Cheng as Chief Medical Officer. He
joined SystImmune from Bristol Myers Squibb, where he served as the
Senior Vice President and Therapeutic Area Oncology Head,
overseeing late-stage clinical development of the oncology
portfolio. Dr. Cheng succeeds Dr. Martin
Olivo, who is leaving SystImmune to pursue external
opportunities.
![(PRNewsfoto/SystImmune Inc.) (PRNewsfoto/SystImmune Inc.)](https://mma.prnewswire.com/media/2053215/SystImmune_Logo_1.jpg)
"I am excited to welcome Dr. Cheng to our leadership team," said
Jie D'Elia, Ph.D., Chief Executive Officer of SystImmune. "His
global oncology development expertise and in-depth regulatory
knowledge will accelerate our efforts to advance SystImmune's
pipeline and transform patient care. On behalf of the SystImmune
team, I want to express our deep appreciation to Dr. Martin Olivo for his dedication and
contributions to SystImmune. We wish him well in his future
endeavors."
Dr. Yi Zhu, Chairman of
SystImmune, stated "Dr. Cheng brings a wealth of expertise and a
remarkable track record in oncology drug development, making him an
invaluable addition to SystImmune's executive leadership team."
Dr. Cheng's career spans both the pharmaceutical industry and
academia, where he has consistently demonstrated exceptional
leadership and a passion for advancing cancer treatments. Under Dr.
Cheng's leadership, BMS developed and received regulatory approval
for multiple important medicines, including Nivolumab, Ipilimumab,
Relatlimab, and Repotrectinib. His strategic vision also
enhanced BMS's internal and collaboration portfolio.
Previously, Dr. Cheng served as Vice President and Oncology
Therapeutic Area Head at Merck Research Laboratories (MRL) and led
teams in securing approvals for Pembrolizumab and Lenvatinib across
multiple oncology indications. Prior to his career in the
pharmaceutical industry, Dr. Cheng had a successful academic career
at Fox Chase Cancer Center, where he conducted groundbreaking
research as the principal investigator in tumor stromal biology,
resulting in over 150 original manuscripts and abstracts. Dr. Cheng
received a BS from Marquette University
and an MD from the University of
Minnesota.
About SystImmune
SystImmune is a clinical-stage biopharmaceutical company located
in Redmond, WA. It specializes in
developing innovative cancer treatments using its established drug
development platforms, focusing on bi-specific, multi-specific
antibodies, and antibody-drug conjugates (ADCs). SystImmune has
multiple assets in various stages of clinical trials for solid
tumor and hematologic indications. Alongside ongoing clinical
trials, SystImmune has a robust preclinical pipeline of potential
cancer therapeutics in the discovery or IND-enabling stages,
representing cutting-edge biologics development.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/systimmune-inc-announces-transition-of-chief-medical-officer-302154022.html
SOURCE SystImmune, Inc.